Latest revenue
$27.8M
as of 2026-03-31
Latest net income
$459.0K
as of 2026-03-31
Net margin
1.7%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $212.3M
- Enterprise value
- $212.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $35.95
- 52-wk low
- $16.05
- Beta
- —
- Shares out
- 9.2M
5-year trend
What this company does
ITEM 1. BUSINESS Overview We are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. Our products are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for healthcare systems. We strive to be one of the most innovative and comprehensive providers of effective surgical solutions and are continually seeking to expand our offerings for patients requiring surgical treatments in the United States. We primarily market and sell soft tissue repair and bone fusion products for use in the operating room or other sterile…
AI summary unavailable — showing raw filing excerpt
Generated from SMTI's filing dated 2026-03-24
Key risks
ITEM 1A. RISK FACTORS The risks below are those that we believe are the material risks that we currently face but are not the only risks facing us and our business. If any of these risks actually occur, our business, financial condition and results of operations could be materially adversely affected. Below is a summary of our risk factors with a more detailed discussion following. ●We have had a history of losses, which may continue as we expand our selling efforts. ●Our revenue growth for a particular period is difficult to predict, and a shortfall in forecasted revenues may harm our operating results. ●Failure to manage our growth strategy could harm our business. ●If we are unable to…
AI summary unavailable — showing raw filing excerpt
Generated from SMTI's filing dated 2026-03-24
Profitability
Gross margin
92.7%
2.3%Operating margin
7.1%
191.4%Net margin
-36.4%
226.7%Return on equity
-632.5%
2478.9%Return on assets
-51.5%
369.4%Leverage
Debt / equity
11.28×
813.2%Long-term debt / equity
7.74×
893.9%Debt / assets
91.9%
66.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $27.8M | +18.6% | $459.0K | +113.0% | 1.7% |
Q4 2025 2025-12-31 | $27.5M | +4.6% | $-1.6M | -4.6% | -5.9% |
Q3 2025 2025-09-30 | $26.3M | +21.5% | $-30.4M | -964.2% | -115.5% |
Q2 2025 2025-06-30 | $25.8M | +28.1% | $-2.0M | +42.5% | -7.8% |
Q1 2025 2025-03-31 | $23.4M | +26.4% | $-3.5M | -99.9% | -15.1% |
Q4 2024 2024-12-31 | $26.3M | — | $-1.5M | — | -5.8% |
Q3 2024 2024-09-30 | $21.7M | +35.2% | $-2.9M | -169.5% | -13.2% |
Q2 2024 2024-06-30 | $20.2M | +28.0% | $-3.5M | -91.7% | -17.4% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on SMTI — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns SMTI
Institutional value
$12.4M
Total shares held
737.8K
Distinct holders
31
-21 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 228.8K | $3.9M | +14.9K (+7.0%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 151.4K | $2.6M | — | New |
| 3 | Stonebridge Wealth Management, LLC | 136.9K | $2.4M | +2.0K (+1.5%) | Added |
| 4 | JANE STREET GROUP, LLC | 38.6K | $662.9K | +23.4K (+153.6%) | Added |
| 5 | SALEM INVESTMENT COUNSELORS INC | 38.4K | $659.7K | +27.5K (+252.4%) | Added |
| 6 | BNP PARIBAS FINANCIAL MARKETS | 27.7K | $475.9K | +23.3K (+536.9%) | Added |
| 7 | VANGUARD FIDUCIARY TRUST CO | 25.4K | $435.9K | — | New |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 18.1K | $311.5K | — | New |
| 9 | HSBC HOLDINGS PLC | 17.3K | $301.1K | -13.5K (-43.9%) | Trimmed |
| 10 | Nuveen, LLC | 15.2K | $261.3K | — | New |
| 11 | JPMORGAN CHASE & CO | 6.3K | $108.8K | -717 (-10.2%) | Trimmed |
| 12 | DEUTSCHE BANK AG\ | 4.0K | $68.5K | +0 (+0.0%) | No change |
| 13 | UBS Group AG | 3.3K | $56.5K | -6.3K (-65.6%) | Trimmed |
| 14 | NEW YORK STATE COMMON RETIREMENT FUND | 2.4K | $41.8K | +0 (+0.0%) | No change |
| 15 | RHUMBLINE ADVISERS | 2.2K | $37.3K | -38 (-1.7%) | Trimmed |
| 16 | WELLS FARGO & COMPANY/MN | 1.1K | $18.9K | -2.2K (-66.8%) | Trimmed |
| 17 | Vanguard Global Advisers, LLC | 905 | $15.5K | — | New |
| 18 | Police & Firemen's Retirement System of New Jersey | 783 | $13.5K | +0 (+0.0%) | No change |
| 19 | CITIGROUP INC | 581 | $10.0K | +169 (+41.0%) | Added |
| 20 | Ameritas Investment Partners, Inc. | 313 | $5.4K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once SMTI's latest filing finishes processing.